Back to results
US 8,476,272 B2Granted
Pharmaceutical composition for treatment of type 2 diabetes
AssigneeJiangsu Hengrui Medicine Co., Ltd.
InventorsKaihong Yuan, Piaoyang Sun
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical composition for the treatment of 2 type diabetes, wherein the pharmaceutical composition contains (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic acid methyl ester or its pharmaceutically acceptable salts and metformin or its pharmaceutically acceptable salts (such as hydrochlorate), preparation method thereof and method of treating 2 type diabetes with the composition.
Claims22
A pharmaceutical composition comprising:
- (a) about 3 to 20% by weight of (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic acid methyl ester or the pharmaceutically acceptable salt thereof;
- (b) about 25 to 94% by weight of metformin or a salt thereof;
- (c) about 0.1 to 10% by weight of lubricant;
- and
- (d) about 0 to 35% by weight of binding agent.
2 more elements
A pharmaceutical composition comprising:
- (a) (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic acid methyl ester or a pharmaceutically acceptable salt thereof as a unit dosage of 25 to 500 mg;
- (b) metformin or a salt thereof as a unit dosage of 250, 500, 625, 750, 850, 1000, 1250 or 1500 mg;
- (c) about 1 to 2% by weight of lubricant;
- (d) about 7% by weight of binding agent;
- optionally
- (e) about 10% by weight of diluent;
- and optionally
- (f) about 0.5% by weight of surfactant.
5 more elements
Dependencies are inferred from the claim text.